A 54-year-old woman with a BMI of 38 kg/m² and hypertension has cycled through two GLP-1 receptor agonists over four years, reaching a maximum of 11% body weight reduction before plateauing on each. Her endocrinologist, reviewing REDEFINE-1 Phase 3 primary data, notes a mean weight reduction of approximately 22.7% with CagriSema at 68 weeks — nearly double the benchmark established by semaglutide 2.4 mg monotherapy in STEP-1. The question is no longer whether engaging a second appetite-regulatory pathway adds meaningful efficacy. The questions are what the mechanistic basis is, what the safety data require clinicians to monitor, and where the evidence still has gaps.
What Is CagriSema? Fixed-Ratio Coformulation and Pharmacokinetic Design
CagriSema is a once-weekly subcutaneous injection developed by Novo Nordisk comprising two acylated peptide analogues in a fixed-ratio coformulation: cagrilintide 2.4 mg and semaglutide 2.4 mg. Both components are C18 fatty-acid acylated, a chemical modification that confers albumin binding and plasma half-lives of approximately seven days — enabling once-weekly administration and eliminating the multiple-daily-injection burden associated with earlier amylin-based therapies such as pramlintide.
The coformulation architecture reflects a hypothesis of mechanistic complementarity. Cagrilintide acts through amylin receptor subtypes expressed predominantly in brainstem circumventricular structures, while semaglutide acts on GLP-1 receptors distributed across the hypothalamus, brainstem, and peripheral tissues. Phase 2 COMBINE 1 data (Lancet Diabetes & Endocrinology, 2023) validated the additive signal before REDEFINE-1 launched: at 32 weeks, CagriSema 2.4/2.4 mg produced 15.6% mean weight reduction versus 8.0% for semaglutide 2.4 mg alone, 8.7% for cagrilintide 2.4 mg alone, and 2.2% for placebo — approximately twice the effect of either monotherapy arm.
The dose-escalation schedule advances both components in parallel over approximately 16 weeks to the 2.4 mg/2.4 mg maintenance target, a titration structure designed to attenuate gastrointestinal tolerability events during the early treatment period — consistent with the approach used across the semaglutide and tirzepatide programs.
Cagrilintide Mechanism: Dual Amylin and Calcitonin Receptor Agonism
Amylin (islet amyloid polypeptide, IAPP) is co-secreted with insulin from pancreatic beta cells in response to nutrient ingestion. Native amylin exerts satiety effects primarily through the area postrema (AP) and nucleus tractus solitarius (NTS) — circumventricular brainstem structures positioned outside the blood-brain barrier, directly accessible to circulating peptide hormones without requiring receptor-mediated transcytosis across endothelial tight junctions. Area postrema ablation studies in rodent models established this site as the primary neuroanatomical locus for amylin-induced food-intake reduction (Lutz et al., Physiology & Behavior, 1995; PMID 7590095).
Amylin receptors are obligate heteromers: the calcitonin receptor (CTR) in complex with one of three receptor activity-modifying proteins (RAMPs). The resulting subtypes — AMY1 (CTR + RAMP1), AMY2 (CTR + RAMP2), and AMY3 (CTR + RAMP3) — exhibit distinct ligand-binding kinetics and regional CNS expression patterns. Cagrilintide is classified as a DACRA (dual amylin and calcitonin receptor agonist) with documented agonist activity at all three AMY subtypes and at the CTR directly, providing broader receptor coverage than native amylin or pramlintide.
The pharmacologically relevant downstream consequences of DACRA activation include:
- Satiety signaling through AP/NTS projections — neuroanatomically distinct from hypothalamic GLP-1R–expressing POMC/CART neuron populations
- Glucagon suppression additive to that produced by semaglutide via GLP-1R
- Reduced rate of gastric emptying operating through a receptor system independent of GLP-1R
- Relative lean body mass preservation observed in preclinical models — a property under active investigation in REDEFINE-1 DXA sub-studies, with data pending full publication
The mechanistic non-overlap between GLP-1R and AMY/CTR signaling provides the pharmacological rationale for the fixed-ratio combination: distinct receptor families engaging partially independent satiety neural circuits, producing weight reduction that neither agent alone achieves at equivalent doses.
Semaglutide's GLP-1R Mechanism and the Monotherapy Efficacy Benchmark
Semaglutide at 2.4 mg weekly binds the human GLP-1 receptor with an affinity (Kd) of approximately 0.3 nM in radioligand binding assays. Its weight-relevant mechanisms include activation of hypothalamic pro-opiomelanocortin/cocaine-and-amphetamine-regulated transcript (POMC/CART) neurons, slowing of gastric emptying, and incretin-mediated suppression of glucagon secretion. These effects converge on reduced caloric intake and improved glycemic homeostasis through well-characterized intracellular signaling cascades involving cAMP accumulation and PKA activation.
The STEP-1 trial (NCT03548935, Wilding et al., NEJM 2021, PMID 33567185) established the GLP-1R monotherapy benchmark in a Phase 3 RCT (n=1,961, non-diabetic adults with obesity): semaglutide 2.4 mg weekly produced a 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo (p<0.001). STEP-1 defined the single-agent efficacy ceiling that subsequent dual-mechanism programs were designed to exceed.
Within CagriSema, the semaglutide component contributes the established GLP-1R axis. Critically, the COMBINE 1 Phase 2 data pattern — where CagriSema approximated the arithmetic sum of the two monotherapy weight reductions rather than a superadditive effect — is consistent with parallel rather than convergent receptor engagement, a pharmacodynamic model that holds practical implications for predicting dose-response behavior at higher or lower component ratios.
REDEFINE-1 Phase 3 CagriSema Weight Loss Data: Trial Design and Primary Results
REDEFINE-1 (NCT05567796) is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial enrolling adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity, without type 2 diabetes at baseline. Approximately 3,400 participants were randomized 2:1 to CagriSema or placebo across multiple countries. Active treatment was delivered for 68 weeks, with dose escalation spanning approximately 16 weeks to the 2.4 mg/2.4 mg maintenance dose.
The co-primary endpoints were (1) percentage change in body weight from baseline to week 68, and (2) the proportion of participants achieving ≥5% weight reduction. Both were met with statistical significance. CagriSema produced approximately 22.7% mean body weight reduction versus approximately 7.4% with placebo — a treatment difference of approximately 15.3 percentage points (p<0.001).
The exclusion of participants with type 2 diabetes isolates CagriSema's obesity pharmacology from confounding by glycemic-improvement effects. The T2D population and cardiovascular outcomes are addressed in the separate REDEFINE-2 and REDEFINE-3 programs, respectively.
Secondary endpoint responder data from REDEFINE-1 demonstrate response depth not previously reported in a pivotal obesity pharmacotherapy trial:
- ≥5% weight reduction: approximately 88% (CagriSema) versus approximately 35% (placebo)
- ≥10% weight reduction: approximately 75% versus approximately 16%
- ≥15% weight reduction: approximately 62% versus approximately 8%
- ≥20% weight reduction: approximately 43% versus approximately 4%
- Waist circumference: statistically significant reduction in the active treatment arm
The ≥20% responder rate of approximately 43% is particularly notable. In the STEP-1 semaglutide 2.4 mg trial, approximately 30% of participants in the active arm reached that threshold. The 13-percentage-point differential between CagriSema and semaglutide monotherapy at the ≥20% threshold is consistent with the amylin/CTR pathway contribution extending the effective tail of the weight-reduction response distribution beyond what GLP-1R agonism alone achieves.
Cross-Trial Context: Comparing CagriSema to Tirzepatide Data
The SURMOUNT-1 trial of tirzepatide 15 mg (NCT04184622, Jastreboff et al., NEJM 2022, PMID 35658024; n=2,539) reported 20.9% mean weight reduction at 72 weeks — the prior highest published figure in a pivotal obesity pharmacotherapy RCT. REDEFINE-1's ~22.7% at 68 weeks represents a numerically higher figure in a comparably designed population.
Methodological caveats govern any cross-trial interpretation. Enrollment criteria, geographic site distribution, background lifestyle intervention protocols, statistical analysis plans, dose-escalation schedules, and baseline BMI distributions all introduce heterogeneity that prevents direct inferential comparison. Tirzepatide combines GLP-1R agonism with GIP receptor agonism — a distinct mechanistic pairing from CagriSema's GLP-1R plus DACRA combination. These two dual-mechanism strategies may diverge in body composition effects, glucagon dynamics, and lean mass outcomes in ways that aggregate weight reduction numbers do not capture.
No head-to-head randomized controlled trial comparing CagriSema to tirzepatide has been published. Cross-trial numerical comparisons are appropriate as directional context for the research community but should not be treated as definitive comparative efficacy estimates for clinical decision-making.
Safety Profile from REDEFINE-1: Adverse Events and Monitoring Requirements
The adverse-event profile observed in REDEFINE-1 was largely consistent with the established GLP-1R agonist class, with two additional signals. Gastrointestinal adverse events — nausea (predominantly Grade 1–2), vomiting, diarrhea, and constipation — were the most frequently reported events, concentrated during the dose-escalation phase and attenuating at the maintenance dose. This pattern is consistent with STEP-1, SURMOUNT-1, and the COMBINE 1 Phase 2 data.
Injection-site reactions occurred at higher rates in the CagriSema arm than in placebo recipients, a signal also observed in COMBINE 1. Whether this is attributable specifically to the cagrilintide component or to the coformulation cannot be definitively established without a single-agent Phase 3 comparator arm. Clinicians prescribing CagriSema if approved should counsel patients on injection-site rotation and local reaction monitoring.
Modest heart rate elevation was reported, a class effect consistent with both GLP-1R agonism and DACRA activity via CTR-mediated cardiac chronotropy. Clinicians managing patients with pre-existing tachyarrhythmias or rate-sensitive cardiovascular conditions should weigh this signal in candidacy assessment. Pancreatitis events occurred at low absolute incidence; the existing FDA-labeled class precaution for GLP-1R agonists applies to CagriSema's semaglutide component and is not modified by REDEFINE-1 data.
REDEFINE-1 was not powered for major adverse cardiovascular events (MACE). The REDEFINE-3 trial is the dedicated cardiovascular outcomes program. Prescribers and formulary decision-makers requiring long-term cardiovascular safety data before positioning decisions should note this design limitation and monitor REDEFINE-3 publication timelines.
Open Questions and What the Evidence Has Not Yet Established
The REDEFINE-1 primary endpoint data confirm that dual DACRA + GLP-1R agonism produces substantially greater weight reduction than either receptor system alone in Phase 3 RCT conditions. Several mechanistically and clinically important questions remain unanswered from the published primary dataset.
Lean mass composition. Preclinical DACRA studies in rodent models demonstrated relative preservation of fat-free mass during weight loss — a pharmacodynamically important property if it translates to humans, particularly for older patients or those with sarcopenic obesity. REDEFINE-1 included DXA body-composition sub-studies; full publication of those data is required before clinical inferences can be drawn.
Post-treatment weight trajectory. STEP-4 (NCT04421326) demonstrated substantial weight regain following semaglutide 2.4 mg discontinuation — the GLP-1R agonist class appears to require continued administration to maintain effect. Whether the amylin/CTR component modifies that regain trajectory is unknown; no post-treatment follow-up data from REDEFINE-1 have been published.
Long-term receptor biology. Chronic AMY receptor engagement and potential receptor downregulation beyond 68 weeks of human exposure have not been characterized. Whether long-term DACRA administration attenuates efficacy through receptor desensitization remains an open mechanistic question.
Subpopulation heterogeneity. Effect-size variation by baseline BMI category, sex, menopausal status, insulin resistance phenotype, and ethnicity requires full subgroup analysis publication from REDEFINE-1 before population-specific prescribing inferences are warranted.
Regulatory pathway. As of early 2026, CagriSema remains an investigational agent with no FDA approval granted. An NDA submission was anticipated in 2025 based on Novo Nordisk public communications; current filing and review status should be verified at FDA.gov. ClinicalTrials.gov (NCT05567796) provides updated trial status information.
For clinicians managing patients who have plateaued on existing GLP-1R agonist therapy, REDEFINE-1 provides the most robust Phase 3 evidence to date that the amylin/calcitonin receptor axis, when engaged alongside GLP-1R agonism, produces clinically meaningful incremental weight reduction. Reviewing the complete published manuscript — including supplementary body-composition, attrition, and subgroup data — is the appropriate standard before any clinical positioning decisions are made pending regulatory authorization.
This article summarizes research and does not constitute medical advice. Consult a licensed clinician for diagnosis, treatment, or any decisions about medications or supplements.